News

IBM’s Big Data analytics technologies will be put to work on bacterial genetics and drug susceptibility tests to better understand the genomic mechanisms that cause resistance to antibiotics.

Mylan previously sued Teva alleging that Teva’s Abbreviated New Drug Application (ANDA) for this product infringed four Mylan patents covering Perforomist. After a full trial, the Court entered

The Australian and Philippine patents have been allowed with a very broad range of claims to a large number of families of chemical structure compositions, pharmaceutical compositions, methods

The company said that the new use is for people 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. So far, H1-antihistamines have

Radiation proctitis (RP) is a significant unmet medical need, with no well-established standard of care. Access is actively seeking marketing partners globally for ProctiGard™. Access Pharmaceuticals president and

Lemtrada is supported by a clinical development program that involved about 1,500 patients and 5,400 patient-years of follow-up. The approval in Brazil follows the recent approvals of Lemtrada

The company said that if approved, empagliflozin will be marketed under the name Jardiance. Empagliflozin belongs to the SGLT2 inhibitor class of drugs that targets glucose directly and

The decision to return the rights of tozadenant has been made on the assessment of UCB’s early and late stage clinical development pipeline as well as its preclinical

The European Medicines Agency’s (EMA) CHMP has issued positive opinions for the conditional marketing authorizations of Vynfinit, Folcepri and Neocepri to treat adult patients with folate receptor-positive, platinum-resistant,